![](/-/media/images/experience-feature-images/2023/astellasacquiresivericbio_social.jpg?rev=9a92a47f1b01406e8b0ce07d1be621f3&la=en&h=800&w=1600&hash=9405F7C48D623CA5BF0F24D110FFA6AC)
Astellas acquires Iveric bio
Client(s) Astellas Pharma Inc.
Jones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.